List of Excipients in Branded Drug NEO-POLY-BAC HYDRO

« Back to Dashboard

Generic Drugs Containing NEO-POLY-BAC HYDRO

Company	Ingredient	NDC	Excipient
Butler Animal Health Supply	neomycin sulfate and polymyxin b sulfate, bacitracin zinc and hydrocortisone	11695-1406	MINERAL OIL
Butler Animal Health Supply	neomycin sulfate and polymyxin b sulfate, bacitracin zinc and hydrocortisone	11695-1406	PETROLATUM

What are the Most Frequently-Used Excipients in NEO-POLY-BAC HYDRO?

# Of NDCs	Excipient
1	MINERAL OIL
1	PETROLATUM

NEO-POLY-BAC-HC Excipient Strategy and Commercial Opportunities

Last updated: September 28, 2026

NEO-POLY-BAC-HC is a legacy ophthalmic ointment combining bacitracin zinc, neomycin sulfate, polymyxin B sulfate, and hydrocortisone. Its commercial opportunity is primarily in generic substitution, hospital supply, private-label manufacturing, preservative-free packaging, and improved ophthalmic delivery. The core formulation is simple, but product differentiation can come from excipient purity, ocular tolerability, reduced visual blurring, tube performance, stability, and supply reliability.

This analysis treats "NEO-POLY-BAC HYDRO" as NEO-POLY-BAC-HC ophthalmic ointment. The labeled reference product contains bacitracin zinc, neomycin sulfate, polymyxin B sulfate, and hydrocortisone in a mineral-oil and petrolatum base.[1]

What is NEO-POLY-BAC-HC and what formulation does it use?

NEO-POLY-BAC-HC is a prescription ophthalmic ointment for steroid-responsive inflammatory ocular conditions where bacterial infection or a risk of bacterial infection exists. The product combines three antibacterial agents with hydrocortisone, a corticosteroid.[1]

Component	Function	Labeled concentration or strength
Bacitracin zinc	Antibacterial agent	400 units/g
Neomycin sulfate	Aminoglycoside antibacterial	3.5 mg/g
Polymyxin B sulfate	Antibacterial agent	10,000 units/g
Hydrocortisone	Corticosteroid	10 mg/g
Mineral oil	Ointment vehicle and emollient	Inactive
Petrolatum	Continuous ophthalmic base	Inactive

The product is an anhydrous ophthalmic ointment. Mineral oil and petrolatum provide the vehicle, lubrication, and residence time on the ocular surface. The base avoids the preservative burden associated with multidose aqueous ophthalmic drops, but it can cause temporary blurred vision and may be less acceptable for daytime use.

What excipients are currently used?

The labeled inactive ingredients are mineral oil and white petrolatum or petrolatum-type ophthalmic base materials, depending on the product presentation and labeling version.[1] The formulation strategy is conventional:

• Mineral oil adjusts spreadability and softening behavior.
• Petrolatum supplies the semisolid matrix.
• The anhydrous base limits microbial growth without requiring a conventional aqueous preservative.
• The ointment supports prolonged contact with the conjunctival sac.

The commercial weakness is that a basic petrolatum-mineral-oil vehicle offers limited product differentiation. Competitors can usually reproduce the broad vehicle concept, subject to pharmaceutical equivalence and product-specific development work.

What excipient opportunities exist for NEO-POLY-BAC-HC?

The strongest opportunities are in vehicle refinement, packaging, ocular comfort, and manufacturing consistency. A new excipient must not materially alter the active-ingredient release profile, local tolerability, microbiological quality, or therapeutic equivalence.

1. Lower-blur ophthalmic vehicles

Petrolatum-heavy ointments can produce prolonged visual blur. A developer could evaluate:

• Lower-viscosity white petrolatum systems.
• Controlled ratios of mineral oil and petrolatum.
• Microcrystalline wax or paraffin adjustments.
• Selected ophthalmic-grade polyolefin or hydrocarbon materials.
• Semisolid systems that melt or spread at ocular-surface temperature.

The regulatory risk is that reducing viscosity can shorten ocular residence time or alter drug release. A lower-blur product must demonstrate acceptable content uniformity, extrusion, spreadability, in vitro release, and clinical performance where required.

2. Improved ocular-surface tolerability

Excipient screening should exclude materials associated with irritation, sensitization, or inconsistent purity. Key attributes include:

• Low peroxide value.
• Low acid value.
• Controlled hydrocarbon composition.
• Low particulate burden.
• Low elemental impurity profile.
• Absence of residual solvents.
• Compatibility with aminoglycosides, polymyxin B, bacitracin, and hydrocortisone.

A high-purity hydrocarbon system could support a premium hospital or specialty-pharmacy position if it reduces irritation or batch-to-batch variability. The commercial claim would require supporting data and could not rely on excipient grade alone.

3. Improved suspension or dispersion control

The active ingredients do not all behave identically in an anhydrous base. Hydrocortisone and bacitracin zinc have different particle and dispersion characteristics from the sulfate salts. Development work should focus on:

• Particle-size distribution.
• Deagglomeration.
• Uniform active distribution through the tube.
• Sedimentation or settling during storage.
• Shear history during mixing.
• Homogeneity at beginning, middle, and end of tube extrusion.

A formulation that improves dose uniformity could have a practical manufacturing advantage even if the final excipient composition remains close to the reference product.

4. Packaging-compatible excipients

Ophthalmic ointments depend heavily on container performance. Excipient selection should be assessed alongside:

• Aluminum versus laminated plastic tubes.
• Internal coatings.
• Tip geometry.
• Tamper-evident closures.
• Extractables and leachables.
• Oxygen and moisture transmission.
• Product recovery from the tube.
• Residual product after normal use.

The vehicle can interact with tube coatings, elastomers, and adhesives. Hydrocarbon migration, metal ion contamination, and active adsorption should be part of the compatibility program.

What regulatory pathway applies to NEO-POLY-BAC-HC generics?

A conventional generic would generally pursue an ANDA if the applicant can demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. A formulation with materially different excipients, delivery characteristics, or clinical behavior may require a 505(b)(2) pathway rather than a standard ANDA.

Development route	Commercial use	Main requirement
ANDA	Conventional generic ointment	Same active ingredients, dosage form, route, strength, and acceptable inactive ingredients, with required equivalence evidence
505(b)(2) NDA	Reformulated or differentiated product	FDA reliance on existing data combined with new development data
New NDA	Major new formulation or clinical positioning	Full development package appropriate to the proposed claims

FDA guidance for ophthalmic products emphasizes pharmaceutical quality, sterility, container-closure performance, and product-specific equivalence considerations.[2] The applicant should assume that a novel excipient system will increase regulatory burden unless the change is clearly supported by established use and equivalence data.

What FDA status and Orange Book issues matter?

The product is a legacy prescription ophthalmic combination rather than a biologic. Biosimilar regulation therefore does not apply. The commercial pathway is generic-drug regulation, not a 351(k) biosimilar pathway.

Orange Book diligence should address:

• The current reference listed drug.
• Any listed patents or exclusivity.
• The correct dosage form and route.
• Product-specific labeling differences.
• Whether the reference product remains commercially available.
• Whether the proposed formulation can qualify for ANDA approval.

For a legacy antibiotic-steroid ophthalmic ointment, market entry risk is more likely to arise from reference-product identification, formulation equivalence, manufacturing validation, and supply-chain execution than from a long-duration new-molecule patent estate. FDA Drugs@FDA and the Orange Book remain the controlling sources for current approval, patent, exclusivity, and reference-product information.[3,4]

What patent protection covers NEO-POLY-BAC-HC?

The likely patent position is limited compared with newer ophthalmic products. The active ingredients are old, and the basic petrolatum-mineral-oil vehicle is conventional. Potentially relevant protection would more likely concern:

• A specific formulation ratio.
• Particle-size control.
• Stabilization of hydrocortisone or antibiotic components.
• Tube or applicator design.
• Manufacturing process controls.
• A new low-blur or extended-residence vehicle.
• A new indication or dosing method.

Are there Paragraph IV challenges?

A Paragraph IV certification is relevant only if an applicant is challenging a currently listed patent in an ANDA. No reliable commercial conclusion should be drawn from the product name alone. A current Orange Book check is required for the precise reference product and formulation.

For a new entrant, the practical sequence is:

1. Confirm the reference listed drug.
2. Review current Orange Book patent listings.
3. Check FDA exclusivity data.
4. Review Federal Circuit and district-court litigation records.
5. Determine whether any listed claims cover the proposed formulation.
6. Select Paragraph III, Paragraph IV, or a different regulatory route.

Because the active combination is mature, a new formulation patent may offer more strategic value than attempting to enforce broad claims around the active ingredients themselves.

How strong is the patent estate for NEO-POLY-BAC-HC?

The underlying product concept has low apparent composition-of-matter strength. Its commercial defensibility would depend on execution-based barriers.

Patent category	Expected strategic value	Likely durability
Active-ingredient composition	Low	Weak for legacy actives
Basic petrolatum/mineral-oil vehicle	Low	Vulnerable to design-around
Specific excipient ratio	Moderate if technically supported	Dependent on claim scope and data
Low-blur delivery system	Moderate to high	Potentially differentiated
Tube and applicator design	Moderate	Vulnerable to alternative packaging
Manufacturing process	Moderate	Useful as a trade-secret barrier
New dosing or indication	Variable	Depends on clinical and regulatory support

A patent strategy should prioritize measurable product attributes rather than generic statements that the product is an ophthalmic ointment. Useful claim targets could include a defined rheological profile, active-particle distribution, release behavior, tube recovery, or stability profile. The claims would need credible technical data to withstand obviousness and enablement challenges.

What commercial opportunities exist for NEO-POLY-BAC-HC?

Generic and private-label supply

The most immediate opportunity is a reliable generic or contract-manufactured product for retail pharmacies, hospitals, ophthalmology practices, and government purchasers. The product has a familiar active combination and does not require biologic manufacturing.

Commercial success would depend on:

• Stable access to bacitracin zinc, neomycin sulfate, and polymyxin B sulfate.
• Consistent ophthalmic-grade petrolatum and mineral oil.
• Validated aseptic or sterile manufacturing.
• Competitive tube-fill economics.
• High service levels during shortage periods.
• A reliable ANDA holder or contract-manufacturing structure.

Preservative-free positioning

The anhydrous ointment format already avoids conventional aqueous preservatives. A manufacturer could position the product around a preservative-free base, provided the labeling and quality data support the claim. This may appeal to patients with ocular-surface sensitivity, chronic ophthalmic exposure, or preservative intolerance.

The claim has limited differentiation if competitors also use anhydrous preservative-free ointments. It becomes more valuable when combined with improved tolerability, lower blur, or better packaging.

Hospital and institutional contracts

Institutional buyers may value:

• Consistent availability.
• Unit-dose or smaller tube presentations.
• Tamper-evident packaging.
• Documented extractables and leachables control.
• Simplified formulary substitution.
• Stable pricing.
• Domestic or diversified supply.

A smaller tube can reduce waste and improve hygiene, but it may raise packaging and filling costs. A unit-dose format could require a separate regulatory and stability assessment.

Ophthalmology-focused product line

The product could anchor a broader ophthalmic portfolio that includes:

• Antibiotic ointments.
• Steroid ophthalmic products.
• Antibiotic-steroid drops.
• Preservative-free lubricants.
• Postoperative ocular-surface products.
• Veterinary ophthalmic products, where separately authorized.

The portfolio strategy is commercially stronger than a single-product launch because it can share sales channels, quality systems, ophthalmic manufacturing capacity, and distributor relationships.

How does NEO-POLY-BAC-HC compare with competing products?

Product type	Main advantage	Main limitation
Antibiotic-only ophthalmic ointment	Avoids steroid-related risks	Less useful when inflammation requires corticosteroid treatment
Antibiotic-steroid ophthalmic drops	Better daytime acceptability	May require preservatives and more frequent dosing
Antibiotic-steroid ophthalmic ointment	Longer residence and lubrication	Blurred vision and semisolid dosing
Single-antibiotic product	Simpler formulation and lower active complexity	Narrower antibacterial coverage
Compounded ophthalmic formulation	Customizable strength or vehicle	Greater quality, sterility, and supply variability
NEO-POLY-BAC-HC generic	Familiar combination and established dosage form	Limited differentiation without vehicle or packaging improvements

The principal competitive threat is not a biosimilar. It is substitution by antibiotic-only products, corticosteroid-only products, drops, alternative ointments, and compounded products.

What manufacturing and intellectual-property barriers matter?

Manufacturing is the main technical barrier. The product requires control of:

• Sterile or validated low-bioburden processing.
• Active dispersion and content uniformity.
• Ointment rheology.
• Tube filling and seal integrity.
• Metal and particulate control.
• Long-term and accelerated stability.
• Microbial limits or sterility testing.
• Container-closure integrity.
• In-use performance.

The three-antibiotic combination increases analytical complexity. The manufacturer must quantify each active and control degradation or interaction products. Polymyxin B is itself a mixture of related components, which can complicate analytical characterization and release specifications.

Trade secrets may provide more practical protection than patents in mixing order, temperature control, homogenization, filling parameters, and active dispersion. These barriers are difficult for a competitor to observe directly but do not prevent a technically competent alternative formulation.

What generic launch scenarios exist?

Launch scenario	Product proposition	Risk level
Standard ANDA	Close equivalent to the reference ointment	Lowest development risk, limited differentiation
Premium preservative-free generic	Emphasizes anhydrous, preservative-free delivery	Moderate
Lower-blur ointment	Modified vehicle and rheology	Moderate to high regulatory risk
Unit-dose ophthalmic presentation	Hygiene and institutional convenience	Moderate
Private-label product	Distributor or pharmacy branding	Commercially dependent on supply contracts
505(b)(2) reformulation	New vehicle, dosing profile, or clinical positioning	Highest development cost and regulatory risk

The best risk-adjusted strategy is usually a conventional equivalent product followed by a differentiated vehicle only after manufacturing and market access are established. Launching directly with a novel excipient system increases formulation, regulatory, and intellectual-property risk.

What is the revenue opportunity?

Public revenue estimates should be treated cautiously because legacy ophthalmic ointment sales are distributed across branded, generic, institutional, and private-label channels. The product is unlikely to support new-molecular-entity pricing. Its value lies in recurring volume, supply reliability, and manufacturing efficiency.

Revenue drivers include:

• Number of approved generic competitors.
• Reimbursement and formulary status.
• Retail versus institutional mix.
• Tube size and unit economics.
• Shortage conditions.
• Active-ingredient procurement costs.
• Contract-manufacturing utilization.
• Ability to bundle the product with an ophthalmic portfolio.

A differentiated excipient strategy can support modest price premiums only if it produces a visible benefit, such as better extrusion, lower blur, reduced irritation, improved tube recovery, or longer stability. Excipient novelty alone is unlikely to justify premium pricing.

Key Takeaways

• NEO-POLY-BAC-HC is an ophthalmic antibiotic-steroid ointment containing bacitracin zinc, neomycin sulfate, polymyxin B sulfate, and hydrocortisone.
• Its labeled vehicle is based on mineral oil and petrolatum.
• The strongest formulation opportunities are lower blur, improved rheology, active uniformity, ocular tolerability, and packaging compatibility.
• The product is regulated as a conventional prescription drug, not a biologic or biosimilar.
• A conventional generic would generally target the ANDA pathway; materially modified products may require a 505(b)(2) strategy.
• The active ingredients and basic ointment concept offer limited composition-of-matter patent strength.
• New value is more likely to come from vehicle patents, packaging, manufacturing know-how, and institutional supply contracts.
• The most attractive commercial model is a reliable generic or private-label product supported by a broader ophthalmic portfolio.
• The main barriers are sterile manufacturing, analytical control of the multi-active formulation, tube compatibility, and regulatory equivalence.

FAQs

Is NEO-POLY-BAC-HC preservative-free?

The anhydrous ointment format uses mineral oil and petrolatum rather than a conventional aqueous preservative system. The exact preservative-free claim must match the current approved labeling.

Can a new excipient be patented for NEO-POLY-BAC-HC?

Yes. Patentable subject matter could include a defined vehicle composition, rheological range, active dispersion profile, release characteristic, tube system, or manufacturing method. Broad claims covering petrolatum and mineral oil alone would likely face significant validity and design-around challenges.

Is hydrocortisone the main commercial differentiator?

Hydrocortisone differentiates the product from antibiotic-only ophthalmic ointments, but it also creates steroid-related labeling and clinical-use limitations. The more defensible commercial differentiation may come from delivery performance and packaging.

Does NEO-POLY-BAC-HC face biosimilar competition?

No. It is a small-molecule combination product. Competition would come from generic ophthalmic ointments, drops, alternative antibiotic-steroid products, and compounded preparations.

What is the most attractive reformulation opportunity?

A preservative-free, lower-blur ointment with robust active uniformity and improved tube recovery offers the clearest commercial opportunity. The formulation must preserve sterility, ocular tolerability, stability, and equivalence to the reference product.

References

1. Bausch & Lomb Incorporated. (n.d.). Neo-Poly-Bac-HC ophthalmic ointment: Prescribing information. U.S. Food and Drug Administration labeling database.

2. U.S. Food and Drug Administration. (2023). Quality considerations for topical ophthalmic drug products: Guidance for industry. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book